AstraZeneca’s Q1 results came in behind our expectations with product sales growth of 1% to $5.6bn. Externalisation revenue (+78%) contributed $550m, leading to group sales of $6.1bn (+5%). NB All growth numbers at CER unless specific otherwise. Currency had a negative impact of 4% on group sales, which ended at 1% growth yoy. Higher-than-expected R&D spend (+11%) was offset to some extent by effective cost containment at COGS (-19%) and SG&A (-8%), culminating in reported opera
24 May 2016
Fragile Q1; pipeline criticality increasing with time
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Fragile Q1; pipeline criticality increasing with time
AstraZeneca PLC (AZN:LON) | 10,721 -2358.6 (-0.2%) | Mkt Cap: 166,198m
- Published:
24 May 2016 -
Author:
Kamla Singh -
Pages:
3
AstraZeneca’s Q1 results came in behind our expectations with product sales growth of 1% to $5.6bn. Externalisation revenue (+78%) contributed $550m, leading to group sales of $6.1bn (+5%). NB All growth numbers at CER unless specific otherwise. Currency had a negative impact of 4% on group sales, which ended at 1% growth yoy. Higher-than-expected R&D spend (+11%) was offset to some extent by effective cost containment at COGS (-19%) and SG&A (-8%), culminating in reported opera